Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 5/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | MPL | P40238 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26552260 | 0.82 | GABRA1 (0.40) | KIF11APPTRPA1ARGABRA1 | |
| SCHEMBL1720610 | 0.80 | NPFFR2 (0.53) | TRPA1AR | |
| SCHEMBL27896750 | 0.78 | PTGS1 (0.36) | KIF11APPPTGS1GABRA1SIGMAR1 | |
| SCHEMBL16141410 | 0.76 | IAPP (0.51) | APPARPTGS1PTGS2 | |
| SCHEMBL4447574 | 0.76 | TRPA1 (0.72) | TRPA1PTGS1GABRA1SIGMAR1TAS1R3 | |
| SCHEMBL4447576 | 0.76 | TRPA1 (0.72) | TRPA1PTGS1GABRA1SIGMAR1TAS1R3 | |
| SCHEMBL4447570 | 0.76 | TRPA1 (0.72) | TRPA1PTGS1GABRA1SIGMAR1TAS1R3 | |
| SCHEMBL29079163 | 0.76 | GAA (0.44) | APPAR | |
| SCHEMBL29110066 | 0.76 | APP (0.42) | KIF11APPARPTGS1MPL | |
| SCHEMBL29110062 | 0.76 | APP (0.42) | KIF11APPARPTGS1MPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730126-B1 | NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INT (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-7244728-B2 | Long acting betamimetics for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-17 | — | — | US | disclosed |
| EP-1730126-A1 | NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092870-A1 | NOVEL BENZOXAZINONE DERIVATIVES USED AS LONG-ACTING BETAMIMETICS FOR TREATING RESPIRATORY ILLNESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | disclosed |
| US-20050209227-A1 | Novel long acting betamimetics for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
| EP-1577306-A1 | novel benzoxazinone derivatives as slow-acting betamimetics and use thereof in treatment of respiratory tract diseases | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209227-A1 | Novel long acting betamimetics for the treatment of respiratory diseases | ADRA1D, ADRB2, ADRA1A | KIF11 2876/4885APP 1805/4885TRPA1 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.